1 |
Akers RM, McFadden TB, Beal WE, Guidry AJ, Farrell HM (1986) Radioimmunoassay for measurement of bovine alpha-lactalbumin in serum, milk and tissue culture media. J Dairy Res 53:419-429.
DOI
ScienceOn
|
2 |
Anandarajah AP (2009) Role of RANKL in bone diseases. Trends Endocrinol Metab 20:88-94.
DOI
ScienceOn
|
3 |
Dyck MK, Lacroix D, Pothier F, Sirard MA (2003) Making recombinant proteins in animals-different systems, different applications. Trends Biotechnol 21:394-399.
DOI
ScienceOn
|
4 |
Echelard Y, Ziome C, Meade H (2006) Production of recombinant therapeutic proteins in the milk of transgenic animals. BioPharm Int 2:1-6.
|
5 |
Filgueira L (2010) Osteoclast differentiation and function. In: Heymann D (ed.), Bone Cancer. Academic Press, pp 59-66.
|
6 |
Grabowski H, Le Bars D, Chene N, Attal J, Malienou- Ngassa R, Puissant C, Houdebine LM (1991) Rabbit whey acidic protein concentration in milk, serum, mammary gland extract, and culture medium. J Dairy Sci 74:4143-4150.
DOI
ScienceOn
|
7 |
Heymann D (2012) Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences. J Bone Oncol 1:2-11.
DOI
ScienceOn
|
8 |
Kostenuik PJ (2005) Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5:618-625.
DOI
ScienceOn
|
9 |
Kues WA, Niemann H (2011) Advances in farm animal transgenesis. Prev Vet Med 102:146-156.
DOI
ScienceOn
|
10 |
Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ (2000) Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157:435-448.
DOI
ScienceOn
|
11 |
Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
DOI
ScienceOn
|
12 |
Lamoureux F, Moriceau G, Picarda G, Rousseau J, Trichet V, Redini F (2010) Regulation of osteoprotegerin proor anti-tumoral activity by bone tumor microenvironment. Lamoureux F et al. Biochim Biophys Acta. 1805:17-24.
|
13 |
Lee CS (2006) Goat -casein promoter directs hGH expression at a high level and in a mammary-specific manner in transgenic mice. Korean J Genetics 28:131-137.
|
14 |
Liu JZ, Hu YY, Ji ZL, Chen SM (2003) Expression of human osteoprotegerin gene in E. coli and bioactivity analysis of expression product (Article in Chinese) Zhonghua Wai Ke Za Zhi 41:641-645.
|
15 |
Maga EA, Murray JD (1995) Mammary gland expression of transgenes and the potential for altering the properties of milk. Biotechnology (NY) 13:1452-1456.
DOI
|
16 |
Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192:463-474.
DOI
ScienceOn
|
17 |
Oh KB, Lee CS (2009) Characterization of double transgenic mice harboring both goat -casein/hGH and goat - casein/hG-CSF hybrid genes. Dev Reprod 13:191-198.
|
18 |
Oh KB, Lee CS (2010) Co-expression of IRES-mediated hG-CSF cDNA and hGH gene under the control of goat -casein promoter. Dev Reprod 14:13-19.
|
19 |
Palmiter RD, Sandgren EP, Avarbock MR, Allen DD, Brinster RL (1991) Helerologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci USA 88:478-482.
DOI
ScienceOn
|
20 |
Persuy MA, Legrain S, Printz C, Stinnakre MG, Lepourry L, Brignon G, Mercier JC (1995) High-level, stageand mammary-tissue-specific expression of a caprine kappa-casein-encoding minigene driven by a beta-casein promoter in transgenic mice. Gene 165:291-296.
DOI
ScienceOn
|
21 |
Reid P, Holen I (2009) Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol 88:1-17.
|
22 |
Ross FP (2006) Osteoclast biology and bone resorption. In: Murray FJ (ed.), Primer of the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 6th ed. American Society for Bone and Mineral Research Publication Office, Durham, pp 30-35.
|
23 |
Rudolph NS (1999) Biopharmaceutical production in transgenic livestock. Trends Biotechnol 17:367-374.
DOI
ScienceOn
|
24 |
Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan H-L, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Program AE, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
DOI
ScienceOn
|
25 |
Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234:137-142.
DOI
ScienceOn
|
26 |
Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T (2000) Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141:3478-3484.
DOI
|
27 |
Wan M, Shi X, Feng X, Cao X (2001) Transcroptional mechanisms of bone morphogenetic protein-induced osteoprotegerin gene expression. J Biol Biochem 276: 10119-10125.
|
28 |
Yan JB, Wang S, Huang WY, Xiao YP, Ren ZR, Huang SZ, Zeng YT (2006) Transgenic mice can express mutant human coagulation factor IX with higher level of clotting activity. Biochem Genet 44:349-360.
|
29 |
Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602.
DOI
ScienceOn
|